The 12th International Symposium on Targeted Alpha Therapy will provide information on the newest developments in preclinical studies, clinical experiences, dosimetry and instrumentation, quality assurance, regulatory, targeting, radiochemistry, and nuclide production and supply. TAT12 will be the first symposium on the African continent, highlighting the close and fruitful collaboration of JRC and University of Pretoria in the development of targeted alpha therapy. The event in Cape Town will network and connect with approx. 300 specialist and leaders on all over the world. It will be the occasion to learn about technological developments and projects accomplishment from specialise presentations and panels.
Full programme available on the event website.
Online registration is open:
- nuclear research
- Monday 27 February 2023, 09:01 - Thursday 2 March 2023, 09:01 (CET)
Practical information
- When
- Monday 27 February 2023, 09:01 - Thursday 2 March 2023, 09:01 (CET)
- Languages
- English
- Website
- TAT 12 website
Description
The JRC is co-organising from 27 February to 2 March 2023 in South-Africa, the 12th International Symposium on Targeted Alpha Therapy (TAT 12). TAT 12 continues a successful series of international symposia on this topic initiated by the Joint Research Centre of the European Commission in Karlsruhe in 1997 and 2000.
Why do we do this & how is this unique
In the current population-ageing scenario, the challenge is to provide high-level healthcare to patients and to make it economically sustainable. Medical radioisotopes play vital role in the diagnosis of cancer, cardiac conditions and other diseases and are increasingly used as therapeutic options. Europe’s Beating Cancer Plan is a key pillar of the European Health Union announced by President von der Leyen in 2020. Launched in 2021, the Cancer Plan sets out a new EU approach to cancer prevention, treatment, and care through an integrated, health-in-all-policies, and multi-stakeholder approach. The plan allows Member States, EU institutions and stakeholders to work closely and in a coordinated manner to bring about change for cancer patients and families.
Third countries will benefit directly from the actions under the Europe’s Beating Cancer Plan through collaborative research within the framework of Horizon Europe. JRC is collaborating with clinical centres worldwide in developing the therapeutic use of alpha-emitters in oncology, in particular Actinium-225 and Bismuth-213. The exceptionally successful recent development of an alpha emitter labelled drug for treatment of prostate cancer has demonstrated that the concept of targeted alpha therapy has the potential to change the future treatment of metastatic cancer in general.
The JRC is committed to supporting the medical applications of nuclear science. The work of JRC on medical radionuclides plays an essential role in the diagnosis and also in the treatment of cancer and other severe diseases. As research organisation, we realise the importance of a strong support for R&I for medical applications of nuclear technology to ensure the best standard of care to patients. For doing this, critical nuclear competencies are needed in all areas to ensure a sustainable use and supply of medical radionuclides, which requires a strong and reliable network of research infrastructures.
This year, colleagues Alfred Morgenstern will be the co-chair of the symposium together with Prof. Mike Sathekge from the University of Pretoria; Frank Bruchertseifer will lead the scientific committee with Mariza Vorster from the University of KwaZulu-Natal.
Background information
We observe a growing importance of radionuclide therapy in Europe and worldwide, which allows to provide a more personalised treatment to patients. In South Africa at the University of Pretoria, cutting edge research is being conducted on the use of radiopharmaceuticals in the diagnosis and treatment of cancer. The JRC is a pioneer in R&D of alpha-emitters in oncology, supporting the development of therapies which target specific tumour cells and address micro-metastases of various cancer types.
The JRC supports hospitals and cancer centres in establishing the capabilities to offer Targeted Alpha Therapy treatment to cancer patients. A collaboration between the Steve Biko hospital in Pretoria and the JRC has built capacity for Targeted Alpha Therapy activity in Africa to treat cancer, particularly prostate cancer patients. This collaboration is a real success story as more than 300 South African prostate cancer patients have benefitted and more patients will benefit in Africa, EU and worldwide from this collaboration.
Scientists, doctors and researchers will participate in the latest discussions, scientific exchange and in focused networking with industry leaders from around the world.
Previous TAT international symposia
TAT 12 continues a successful series of international symposia on this topic initiated by the Joint Research Centre of the European Commission, including meetings in Karlsruhe (1997, 2000), Heidelberg (2002), Düsseldorf (2004), Aachen (2007), Toronto (2009), Berlin (2011), Oak Ridge (2013), Warsaw (2015), Kanazawa (2017) and Ottawa (2019).
For more information, visit TAT12 International Symposium (tat-12.com)
Call for Abstracts
The Scientific Committee invites all interested colleagues to submit oral and/or poster abstracts for the TAT 12 Symposium. The symposium offers an excellent opportunity to network and to share the most up-to-date research in the field of Targeted Alpha Therapy.
View and Download the Call for Abstracts
Alpha Therapy: nuclear waste gives precious lifetime to cancer patients
Nuclear waste helps cancer patients. You find it hard to believe? Discover Targeted Alpha Therapy in this video.
![TAT 12 - International Symposium](https://joint-research-centre.ec.europa.eu/sites/default/files/2022-09/Tat12-Website-banner-09-scaled.jpeg)